<table border="1" cellpadding="0" cellspacing="0" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="94.5pt"></col>
<col width="396.9pt"></col>
<tbody>
<tr>
<td colspan="3" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="bold">Drugs That Interfere with Hemostasis </content>
</paragraph>
</td>
</tr>
<tr>
<td>
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td colspan="2">
<list listtype="unordered" stylecode="Disc">
<item>Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.</item>
<item>Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. </item>
</list>
</td>
</tr>
<tr>
<td>
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td colspan="2">
<paragraph>Monitor patients with concomitant use of diclofenac sodium and misoprostol with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding <content stylecode="italics">[see <linkhtml href="#LINK_0db11b4e-50de-455d-b1c6-b57254776b4c">Warnings and Precautions (5.11)</linkhtml>]</content>. </paragraph>
</td>
</tr>
<tr>
<td colspan="3">
<paragraph>
<content stylecode="bold">Aspirin </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td>
<paragraph>Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone <content stylecode="italics">[see <linkhtml href="#LINK_f7ed22ac-59f0-4ff8-8979-a9efd26d0b01">Warnings and Precautions (5.2)</linkhtml>]</content>. </paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td>
<paragraph>Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding <content stylecode="italics">[see <linkhtml href="#LINK_0db11b4e-50de-455d-b1c6-b57254776b4c">Warnings and Precautions (5.11)</linkhtml>]</content>. </paragraph>
<paragraph>Diclofenac sodium and misoprostol is not a substitute for low dose aspirin for cardiovascular protection. </paragraph>
</td>
</tr>
<tr>
<td colspan="3">
<paragraph>
<content stylecode="bold">ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td>
<list listtype="unordered" stylecode="Disc">
<item>NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).</item>
<item>In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. </item>
</list>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td>
<list listtype="unordered" stylecode="Disc">
<item>The concomitant administration of these drugs should be done with caution. Patients should be adequately hydrated and the clinical need to monitor the renal function should be assessed at the beginning of the concomitant treatment and periodically thereafter. </item>
<item>During concomitant use of diclofenac sodium and misoprostol and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. </item>
<item>During concomitant use of diclofenac sodium and misoprostol and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function <content stylecode="italics">[see <linkhtml href="#LINK_02c33c6e-c8bc-4c70-b5a3-955a17cb6d20">Warnings and Precautions (5.6)</linkhtml>]</content>. </item>
</list>
</td>
</tr>
<tr>
<td colspan="3">
<paragraph>
<content stylecode="bold">Diuretics </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td>
<paragraph>Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis. </paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td>
<paragraph>During concomitant use of diclofenac sodium and misoprostol with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects <content stylecode="italics">[see <linkhtml href="#LINK_02c33c6e-c8bc-4c70-b5a3-955a17cb6d20">Warnings and Precautions (5.6)</linkhtml>]</content>. </paragraph>
</td>
</tr>
<tr>
<td colspan="3">
<paragraph>
<content stylecode="bold">Digoxin </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td>
<paragraph>The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. </paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td>
<paragraph>During concomitant use of diclofenac sodium and misoprostol and digoxin, monitor serum digoxin levels. </paragraph>
</td>
</tr>
<tr>
<td colspan="3">
<paragraph>
<content stylecode="bold">Lithium </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td>
<paragraph>NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis. </paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td>
<paragraph>During concomitant use of diclofenac sodium and misoprostol and lithium, monitor patients for signs of lithium toxicity. </paragraph>
</td>
</tr>
<tr>
<td colspan="3">
<paragraph>
<content stylecode="bold">Methotrexate </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td>
<paragraph>Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction). </paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td>
<paragraph>During concomitant use of diclofenac sodium and misoprostol and methotrexate, monitor patients for methotrexate toxicity. </paragraph>
</td>
</tr>
<tr>
<td colspan="3">
<paragraph>
<content stylecode="bold">Cyclosporine </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td>
<paragraph>Concomitant use of diclofenac and cyclosporine may increase cyclosporineâ€™s nephrotoxicity. </paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td>
<paragraph>During concomitant use of diclofenac sodium and misoprostol and cyclosporine, monitor patients for signs of worsening renal function. </paragraph>
</td>
</tr>
<tr>
<td colspan="3">
<paragraph>
<content stylecode="bold">NSAIDs and Salicylates </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td>
<paragraph>Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy <content stylecode="italics">[see <linkhtml href="#LINK_f7ed22ac-59f0-4ff8-8979-a9efd26d0b01">Warnings and Precautions (5.2)</linkhtml>]</content>. </paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td>
<paragraph>The concomitant use of diclofenac sodium and misoprostol with other NSAIDs or salicylates is not recommended. </paragraph>
</td>
</tr>
<tr>
<td colspan="3">
<paragraph>
<content stylecode="bold">Pemetrexed </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td>
<paragraph>Concomitant use of diclofenac and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information). </paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td>
<paragraph>During concomitant use of diclofenac sodium and misoprostol and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity. </paragraph>
<paragraph>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. </paragraph>
<paragraph>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration. </paragraph>
</td>
</tr>
<tr>
<td colspan="3">
<paragraph>
<content stylecode="bold">Antacids </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td>
<paragraph>Antacids reduce the bioavailability of misoprostol acid. Antacids may also delay absorption of diclofenac. Magnesium-containing antacids exacerbate misoprostol-associated diarrhea. </paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td>
<paragraph>Concomitant use of diclofenac sodium and misoprostol and magnesium-containing antacids is not recommended. </paragraph>
</td>
</tr>
<tr>
<td colspan="3">
<paragraph>
<content stylecode="bold">Corticosteroids </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td>
<paragraph>Concomitant use of corticosteroids with diclofenac may increase the risk of GI ulceration or bleeding. </paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Intervention </content>
</paragraph>
</td>
<td>
<paragraph>Monitor patients with concomitant use of diclofenac sodium and misoprostol with corticosteroids for signs of bleeding <content stylecode="italics">[see <linkhtml href="#LINK_f7ed22ac-59f0-4ff8-8979-a9efd26d0b01">Warnings and Precautions (5.2)</linkhtml>]</content>. </paragraph>
</td>
</tr>
<tr>
<td colspan="3">
<paragraph>
<content stylecode="bold">CYP2C9 Inhibitors or Inducers </content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Clinical Impact: </content>
</paragraph>
</td>
<td>
<paragraph>Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9. Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac <content stylecode="italics">[see <linkhtml href="#LINK_40da22ab-9880-419c-aac4-3222230c217b">Clinical Pharmacology (12.3)</linkhtml>]</content> whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of diclofenac. </paragraph>
</td>
</tr>
<tr>
<td colspan="2">
<paragraph>
<content stylecode="italics">Intervention: </content>
</paragraph>
</td>
<td>
<paragraph>CYP 2C9 inhibitors: When concomitant use of CYP2C9 inhibitors is necessary, the total daily dose of diclofenac should not exceed the lowest recommended dose of diclofenac sodium 50 mg and misoprostol 200 mcg twice daily <content stylecode="italics">[see <linkhtml href="#LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9">Dosage and Administration (2)</linkhtml>]</content>. CYP2C9 inducers: A dosage adjustment may be warranted when diclofenac sodium and misoprostol is administered with CYP2C9 inducers. Administer the separate products of misoprostol and diclofenac if a higher dose of diclofenac is deemed necessary. </paragraph>
</td>
</tr>
</tbody>
</table>